Synthetic RNA Therapeutics in Cancer

  • Han, Youngjin; 
  • Shin, Seung-Hyun; 
  • Lim, Chang Gyu; 
  • Heo, Yong Ho; 
  • Choi, In Young; 
  • ... Kim, Ha Hyung
Citations

WEB OF SCIENCE

14
Citations

SCOPUS

14

초록

ABSTRACT: Recent advances in the RNA delivery system have facilitated the development of a separate field of RNA therapeutics, with modalities including mRNA, microRNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA, and circular (circRNA) that have been incorporated into oncology research. The main advantages of the RNA-based modalities are high flexibility in designing RNA and rapid production for clinical screening. It is challenging to eliminate tumors by tackling a single target in cancer. In the era of precision medicine, RNA-based therapeutic approaches potentially constitute suitable platforms for targeting heterogeneous tumors that possess multiple sub-clonal cancer cell populations. In this review, we discussed how synthetic coding and non-coding RNAs, such as mRNA, miRNA, ASO, and circRNA, can be applied in the development of therapeutics. SIGNIFICANCE STATEMENT: With development of vaccines against coronavirus, RNA-based therapeutics have received attention. Here, the authors discuss different types of RNA-based therapeutics potentially effective against tumor that are highly heterogeneous giving rise to resistance and relapses to the conventional therapeutics. Moreover, this study summarized recent findings suggesting combination approaches of RNA therapeutics and cancer immunotherapy.

키워드

PHASE-I; GASTRIC-CANCER; ANTISENSE OLIGONUCLEOTIDES; MEDIATED DELIVERY; PROSTATE-CANCER; PTEN; GROWTH; PROMOTES; CELLS; INHIBITOR
제목
Synthetic RNA Therapeutics in Cancer
저자
Han, Youngjin; Shin, Seung-Hyun; Lim, Chang Gyu; Heo, Yong Ho; Choi, In Young; Kim, Ha Hyung
DOI
10.1124/jpet.123.001587
발행일
2023-08
유형
Review
저널명
Journal of Pharmacology and Experimental Therapeutics
권
386
호
2
페이지
212 ~ 223